Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about PROG: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No AI portrait yet
| Target | Relation | Type | Str |
|---|---|---|---|
| neurodegenerative_disorders | treats | disease | 0.80 |
| Source | Relation | Type | Str |
|---|---|---|---|
| No incoming edges | |||
Hypotheses where this entity is a therapeutic target
Scientific analyses that reference this entity
No analyses mention this entity
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| P2RY12 inhibition in atherosclerosis mouse model | validation | atherosclerosis | 0.900 | 0.00 | ApoE-deficient mice | proposed | N/A |
| VSMC cholesterol efflux and P2RY12 signaling | exploratory | atherosclerosis | 0.900 | 0.00 | cultured VSMCs | proposed | N/A |
| Leukocyte gene expression analysis in COVID-19 patients | exploratory | COVID-19 | 0.900 | 0.00 | human leukocytes from COVID-19 | proposed | N/A |
| P2RY12 regulation of autophagy in VSMCs | exploratory | atherosclerosis | 0.900 | 0.00 | cultured VSMCs | proposed | N/A |
| TREK-1 regulation of conventional outflow facility in mouse eyes | validation | ocular hypertension | 0.900 | 0.00 | mouse eyes | proposed | N/A |
| DEX effects on TREK-1 currents in human primary TM cells | exploratory | corticosteroid-induced ocular | 0.900 | 0.00 | primary human trabecular meshw | proposed | N/A |
| TREK-1 effects on IOP in DEX-induced mouse OHT model | validation | dexamethasone-induced ocular h | 0.900 | 0.00 | mouse eyes | proposed | N/A |
| DEX effects on K2P channel transcriptome in mouse TM cells | exploratory | corticosteroid-induced ocular | 0.900 | 0.00 | mouse trabecular meshwork cell | proposed | N/A |
| P2RY12-MTOR pathway interaction in VSMCs | exploratory | atherosclerosis | 0.850 | 0.00 | cultured VSMCs | proposed | N/A |
| In vivo autophagy modulation in atherosclerotic mice | validation | atherosclerosis | 0.850 | 0.00 | ApoE-deficient mice | proposed | N/A |
| TREK-1 effects on spontaneous OHT in rats using telemetry | validation | spontaneous ocular hypertensio | 0.800 | 0.00 | rat eyes | proposed | N/A |
| TREK-1 localization in trabecular meshwork by immunohistochemistry | exploratory | ocular hypertension | 0.800 | 0.00 | trabecular meshwork tissue | proposed | N/A |
| s:** - Compare brain penetration in FcRn+/+ vs FcRn-/- mice with engin | falsification | Neuroinflammation | 0.400 | 0.50 | mouse | proposed | $200,000 |
| s:** - Compare uptake with/without magnetic particles using tight junc | falsification | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $120,000 |
| AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Therapy | validation | Parkinson's Disease | 0.400 | 0.50 | mouse | proposed | $280,000 |
| AAV Serotype Comparison for LRRK2 Knockdown in PD | validation | Parkinson's Disease | 0.400 | 0.50 | mouse | proposed | $280,000 |
| Blood-Based Biomarker Panel for Early AD Detection | clinical | Alzheimer's Disease | 0.400 | 0.50 | cell_line | proposed | $220,000 |
| Blood-Brain Barrier Aging and Neurodegeneration — From Leakage to Neur | validation | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $130,000 |
| Gene Therapy: AAV Serotype Comparison for LRRK2 Knockdown | validation | Parkinson's Disease | 0.400 | 0.50 | mouse | proposed | $280,000 |
| Vascular Contribution to Alzheimer's Disease — Beyond Amyloid | validation | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $2,280,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Beyond Activation: Characterizing Microglial Functional Phenotypes. [PMID:34571885] | Lier J, Streit WJ, Bechmann I | Cells | 2021 | 2 |
| The P2RY12 receptor promotes VSMC-derived foam cell formation by inhibiting auto [PMID:32160082] | Pi S, Mao L, Chen J, Shi H, Liu Y, Guo X | Autophagy | 2021 | 2 |
| Identification of mechanosensitive ion channel-related molecular subtypes and ke [PMID:40950697] | Zhang L, Wang L, Wang M, Peng K, Chen H, | Transl Cancer Res | 2025 | 1 |
| Mechano- and Glucocorticoid-Sensitive TREK-1 Channels Regulate Conventional Outf [PMID:41268978] | Redmon SN, Yarishkin O, Rudzitis CN, Lak | Invest Ophthalmol Vis Sci | 2025 | 1 |
| Inflammation alters the expression and activity of the mechanosensitive ion chan [PMID:39789885] | Ren J, Zhan C, Lin Y | Eur J Orthod | 2024 | 1 |
| Mechanosensitive Piezo1 channel in physiology and pathophysiology of the central [PMID:37532007] | Zong B, Yu F, Zhang X, Pang Y, Zhao W, S | Ageing Res Rev | 2023 | 1 |
| NAD(+) metabolism, stemness, the immune response, and cancer. [PMID:33384409] | Navas LE, Carnero A | Signal Transduct Target Ther | 2021 | 1 |
| Convergence between Microglia and Peripheral Macrophages Phenotype during Develo [PMID:31818979] | Grassivaro F, Menon R, Acquaviva M, Otto | J Neurosci | 2020 | 1 |
| Piezo-type mechanosensitive ion channel component 1: a mechano-bioenergetic tran [PMID:41437911] | ["Zhang Y", "Gao C", "Li Y", "Fu Q", "Li | Annals of medicine | 2026 | 0 |
| P2 purinergic receptors in systemic lupus erythematosus: from experimental findi [PMID:41825304] | Renaudineau Y, Brooks W | Current opinion in immunology | 2026 | 0 |
| Constitutive expression of CX3CR1-BAC-Cre introduces minimal off-target effects [PMID:41924777] | Mroue-Ruiz FH, Desai B, Garvin MM, Shehu | Biochemical and biophysical re | 2026 | 0 |
| Direct pharmacological targeting of Piezo1 by Paeoniflorin: a novel therapeutic [PMID:40653265] | ["Li R", "Xia J", "Shi C", "Zhang K", "Q | Journal of advanced research | 2026 | 0 |
| [Advantageous therapeutic pathways and mechanisms of Jianpi Huogu Formula in tre [PMID:41814722] | Li T, Zhang C, Jia Y, Chen WH, Lin N, Zh | Zhongguo Zhong yao za zhi = Zh | 2026 | 0 |
| Differences in mRNA expression of neuroinflammation-related genes in the tempora [PMID:41843422] | Tan THL, McLean C, Christie M, Sanfilipp | Epileptic disorders : internat | 2026 | 0 |
| Clopidogrel Administration Impairs Neurovascular Unit Recovery and Exacerbates A [PMID:41898413] | Paul M, Paul JW, Hinwood M, Hood RJ, Mar | International journal of molec | 2026 | 0 |
| Piezo1: structural pharmacology and mechanotransduction mechanisms. [PMID:40750459] | ["Wang J", "Jing F", "Zhao Y", "You Z", | Trends in pharmacological scie | 2025 | 0 |
| Emerging roles of mechanically activated ion channels in autoimmune disease. [PMID:40194731] | ["Zeng Z", "Chen E", "Xue J"] | Autoimmunity reviews | 2025 | 0 |
| Local soft niches in mechanically heterogeneous primary tumors promote brain met [PMID:40009679] | ["Tang K", "Zheng Y", "Hu G", "Xin Y", " | Science advances | 2025 | 0 |
| Amyloid beta Aβ [PMID:39722451] | ["Lim X", "Willemse L", "Harraz O"] | Biophysical journal | 2025 | 0 |
| Enhancing TREM2 expression activates microglia and modestly mitigates tau pathol [PMID:40122810] | ["Chen Kai", "Li Fuyao", "Zhang Shuwen", | Journal of neuroinflammation | 2025 | 0 |
Multi-agent debates referencing this entity
No debates reference this entity
Hypotheses and analyses mentioning PROG in their description or question text
Score: 0.727 · neurodegeneration · 2026-04-02
## Mechanistic Overview Synthetic Biology BBB Endothelial Cell Reprogramming starts from the claim that modulating TFR1,
Score: 0.718 · neurodegeneration · 2026-04-12
## Mechanistic Overview Disease-Associated Microglia Metabolic Reprogramming starts from the claim that modulating TREM2
Score: 0.701 · neurodegeneration · 2026-04-02
## Mechanistic Overview Microglial Purinergic Reprogramming starts from the claim that modulating P2RY12 within the dise
Score: 0.700 · neurodegeneration · 2026-04-22
## **Molecular Mechanism and Rationale** The molecular foundation of this hypothesis centers on the intricate relations
Score: 0.700 · neurodegeneration · 2026-04-02
## Mechanistic Overview Mechanosensitive Ion Channel Reprogramming starts from the claim that modulating PIEZO1 and KCNK
Score: 0.693 · ALS · 2026-04-26
Score: 0.690 · neurodegeneration · 2026-04-04
## Mechanistic Overview Epigenetic Memory Reprogramming via CRISPRa-Mediated Chromatin Remodeling starts from the claim
Score: 0.672 · neurodegeneration · 2026-04-02
## Mechanistic Overview Metabolic Reprogramming via Microglial Glycolysis Inhibition starts from the claim that modulati
Score: 0.672 · neurodegeneration · 2026-04-02
## Mechanistic Overview FOXO3-Longevity Pathway Epigenetic Reprogramming starts from the claim that modulating FOXO3 wit
Score: 0.672 · neurodegeneration · 2026-04-02
## Mechanistic Overview Partial Neuronal Reprogramming via Modified Yamanaka Cocktail starts from the claim that modulat
Score: 0.665 · neurodegeneration · 2026-04-11
## **Molecular Mechanism and Rationale** Extracellular vesicles (EVs) represent a sophisticated intercellular communica
Score: 0.663 · neurodegeneration · 2026-04-02
## Mechanistic Overview Sphingolipid Metabolism Reprogramming starts from the claim that modulating CERS2 within the dis
Score: 0.662 · unknown disease · 2026-04-04
## Mechanistic Overview Circadian-Metabolic Microglial Reprogramming starts from the claim that modulating CLOCK, BMAL1,
Score: 0.661 · neurodegeneration · 2026-04-11
**Molecular Mechanism and Rationale** Extracellular vesicles (EVs) represent a sophisticated intercellular communicatio
Score: 0.660 · neuroinflammation · 2026-04-21
## Mechanistic Overview Chronic cGAS/STING Hyperactivation Drives Progressive Neurodegeneration Through Sustained Type I